Concanavalin A-targeted mesoporous silica nanoparticles for infection treatment

TL;DR

This study develops Concanavalin A-decorated mesoporous silica nanoparticles loaded with levofloxacin, designed to penetrate bacterial biofilms and enhance antibiotic delivery, offering a promising new approach for treating chronic infections.

Contribution

The paper introduces a novel ConA-functionalized mesoporous silica nanoparticle system for targeted biofilm penetration and improved antibiotic delivery.

Findings

ConA decoration promotes nanoparticle internalization into biofilms.

Enhanced antimicrobial efficacy observed with the nanocarrier.

Potential to reduce side effects compared to conventional treatments.

Abstract

The ability of bacteria to form biofilms hinders any conventional treatment against chronic infections and has serious socio-economic implications. In this sense, a nanocarrier capable of overcoming the barrier of the mucopolysaccharide matrix of the biofilm and releasing its loaded-antibiotic within would be desirable. Herein, a new nanosystem based on levofloxacin (LEVO)-loaded mesoporous silica nanoparticles (MSNs) decorated with lectin Concanavalin A (ConA) has been developed. The presence of ConA promotes its internalization into the biofilm matrix, which increases the antimicrobial efficacy of the antibiotic hosted within the mesopores. This nanodevice is envisioned as a promising alternative to conventional infection treatments by improving the antimicrobial efficacy and reducing side effects.